Physician Views: Key growth driver watch - Hemlibra

New clinical data recently presented for Roche's Hemlibra support the view that it will be a competitor of some significance to current standard-of-care treatments in haemophilia A patients who have not developed inhibitors to factor replacement therapy - see also KOL Views Results: Leading haematologist thinks HAVEN 3 data will likely speed adoption of Hemlibra in non-inhibitor patients.

We are snap-polling haematologists to get a better idea how results from the HAVEN 3 and 4 studies could influence future prescribing decisions…

In the Phase III HAVEN 3 study, adults and adolescents aged 12 years or older without factor VIII inhibitors who received Hemlibra prophylaxis every week or every two weeks showed a 96% and 97% reduction in treated bleeds, respectively, compared to those who received no prophylaxis. In addition, 55.6% of people treated with Hemlibra every week and 60% of people treated with Hemlibra every two weeks experienced zero treated bleeds, compared to 0% of people treated with no prophylaxis.

How do you rate these data?




Very good


In an intra-patient comparison, in patients (n=152) who were previously enrolled in a prospective non-interventional study, once-weekly Hemlibra prophylaxis showed superior efficacy compared to prior factor VIII prophylaxis, the standard of care for people with haemophilia A without factor VIII inhibitors, as demonstrated by a 68% reduction in treated bleeds.

How do you rate these data?




Very good


Additionally, 93.7% (n=89/95) of all participants who completed a treatment preference survey preferred Hemlibra to their previous haemophilia treatment, with 97.8% (n=45/46) of those in the intra-patient comparison preferring Hemlibra to their prior factor VIII prophylaxis.

Would this data have an influence on your own prescribing habits?

Not at all influential

Slightly influential

Somewhat influential

Moderately influential

Extremely influential

There were no unexpected or serious adverse events (AEs) related to Hemlibra, and the most common AEs were consistent with previous studies. The most common AEs occurring in 5% or more of people in the HAVEN 3 study were injection site reactions, joint pain (arthralgia), common cold symptoms (nasopharyngitis), headache, upper respiratory tract infection and influenza.

Taking these data, other available data and clinical trial/real-world experience into account, how satisfied are you currently with the safety profile of Hemlibra?

Not at all satisfied

Slightly satisfied

Moderately satisfied

Very satisfied

Extremely satisfied

In the single-arm Phase III HAVEN 4 study, adults and adolescents aged 12 years or older with or without factor VIII inhibitors receiving Hemlibra prophylaxis every four weeks had a median annualised bleeding rate for treated bleeds of zero with 56.1% of people experiencing zero treated bleeds and 90.2% experiencing three or fewer treated bleeds.

For patients, how desirable would monthly dosing of Hemlibra be?

Very undesirable




Very desirable

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions. Note: FirstWord Polls are powered by Medefield MedePolls, a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties and over 100 markets. To conduct this poll with a different audience, or an entirely different poll, contact us at

To read more Physician Views articles, click here.